Eckert & Ziegler Strahlen und Medizintechnik : Report of the Supervisory Board

Report of the Supervisory Board on the Fiscal Year 2021

Dear Shareholders,

In fiscal year 2021, the Supervisory Board properly fulfilled the tasks incumbent upon it according to the law, the Articles of Association, and the rules of procedure. It continuously monitored the Executive Board and advised it on its corporate management activities. The Supervisory Board was directly involved in all decisions of fundamental importance to the company.

The Executive Board regularly, promptly, and extensively informed the Supervisory

Board about corporate planning, business performance, and strategic progress, as well as the Group's current situation.

The Chairman of the Executive Board also regularly informed the Chairman of the

Supervisory Board outside the Supervisory Board's meetings about current

developments and significant business transactions. Moreover, the Chairman of the Supervisory Board and the Chairman of the Executive Board liaised on a regular basis on issues related to strategy, planning, general business development, the risk situation, risk management, and compliance. A total of six Supervisory Board meetings took place during the period under review. The Remuneration Committee and the Audit Committee each convened 3 times during the reporting period. If necessary, the Supervisory Board also issued authorizations by written procedure.

Resolutions of fundamental importance were either passed on the basis of relevant documentation or after direct discussions with the Executive Board. The participation at the meetings of the Supervisory Board, the Remuneration Committee and the Audit Committee was 100%. The following table shows the individualized participation.

Overview of the Member Participation in Supervisory Board and Committee Meetings for the Fiscal Year 2021
Plenary Sessions of the Supervisory Board	Audit Committee	Remuneration Committee
Atten-dance	Meet- ings	Partici-pation	Atten-dance	Mee-tings	Partici-pation	Atten-dance	Meet- ings	Partici-pation
Prof. Dr. Wolf-gang Maennig (Chair-man)	6	6	100%
Prof. Dr. Helmut Grothe (Deputy Chair-man)	6	6	100%	3	3	100%
Dr. Edgar Löffler	6	6	100%	3	3	100%	3	3	100%
Frank Persch-mann	6	6	100%	3	3	100%	3	3	100%
Albert Rup-precht	6	6	100%	3	3	100%
Jutta Ludwig	6	6	100%	100
Total	100%	100%	100%

KEY TOPICS ADDRESSED BY THE SUPERVISORY BOARD

The following key topics formed the focus of the individual Supervisory Board meetings:

At the meeting on January 19, 2021, the Executive Board mainly reported on the preliminary key figures for the fiscal year 2021, the economic situation and the current status of major projects. The Supervisory Board also discussed the declaration on compliance submitted within the framework of the Corporate Governance Code. Furthermore, the risk report of the company, which describes the most important risk positions and the risk management in the group, was approved and the sustainability report was discussed. The Executive Board also provided information about further steps in China for the Radiopharma division and about current development projects.

The main subject of the meetings on the 25 March and the 14 April 2021 was the review of the annual financial statements and the management reports for the Group and the company. In addition, the Executive Board reported on the economic situation, the Brazilian business, the planned company site in Jintan (China), and on PentixaPharm. The meeting on 2 June 2021 focused primarily on the business figures for the 1st quarter of 2021, the formation of an Audit Committee as well as preparations for the Annual General Meeting.

The Supervisory Board meeting on 10 August 2021 mainly discussed the business figures for the 2nd quarter of 2021 and ongoing projects, including the expansionprojects at the Berlin and Dresden sites. The tasks of the Audit Committee were also determined.

The focus of the meeting on 29 October 2021 was the presentation and approval of the budget for the 2022 financial year as well as the presentation of the business figures for the 3rd quarter of 2021. Further topics were the strategic orientation in the Medical and Isotope Products segments as well as the adjustment of rules of procedure for the Supervisory Board. In addition, a training event on the Act to Strengthen Financial Market Integrity was held and the Declaration of Conformity with the German Corporate Governance Code was approved.

COMMITTEE ACTIVITIES

Remuneration Committee

The members of the Remuneration Committee are:

• • Dr. Edgar Löffler

• • Frank Perschmann

The Remuneration Committee met three time during the reporting period and mainly dealt with the contracts of the Executive Board members. For this purpose, the Remuneration Committee prepared the resolutions of the Supervisory Board on the determination of the performance criteria and the targets for the variable remuneration, the determination and review of the appropriateness of the Executive Board remuneration and the approval of the remuneration report. The Supervisory Board's resolution on the adjustment on the remuneration system for the Executive Board was prepared.

Audit Committee

The members of the Audit Committee are:

• • Frank Perschmann (Chairman)

• • Prof. Dr. Helmut Grothe

• • Dr. Edgar Löffler

• • Albert Rupprecht

The Audit Committee met three times in the financial year 2021.

The meetings focused in particular on monitoring the accounting process and on issues relating to the effectiveness of the internal control system and its further development, the effectiveness of the risk management system, and the internal audit system.

CORPORATE GOVERNANCE PRINCIPLES

In the period under review, the Supervisory Board continued to deal with the further development of the standards of good and responsible corporate governance, taking into account the German Corporate Governance Code as amended on February 7, 2017. On December 3, 2021, the Executive Board and the Supervisory Board issued a new Declaration of Conformity with the German Corporate Governance Code.

Additional details regarding Corporate Governance are available in the Group's Corporate Governance Report, which is published on the Group's website inconnection with the Declaration on Compliance. In the period under review, there were no conflicts of interest among members of the Supervisory Board.

EFFICIENCY REVIEW

The Supervisory Board regularly evaluates how effective it is as a body as a whole and how its committees perform their duties. A comprehensive review was conducted in October 2021. The results were discussed by the Supervisory Board in January 2022. No significant deficiencies were identified. The next review is planned for the current financial year.

TRAINING AND CONTINUING EDUCATION

The members of the Supervisory Board are responsible for the training and continuing education measures required for their tasks, such as on changes in the legal framework, and are supported in this by the company. In the reporting year, an internal seminar took place on the topic of balance sheet control in accordance with the Financial Market Integrity Strengthening Act (FISG), which came into force in July 2021.

AUDIT OF THE ANNUAL FINANCIAL STATEMENTS 2021

The annual financial statements of Eckert & Ziegler Strahlen- und Medizintechnik AG, the consolidated financial statements of the Eckert & Ziegler Group, and the management reports were audited, together with the accounting system, by the auditors appointed by the Annual General Meeting for fiscal year 2021, BDO AG Wirtschaftsprüfungsgesellschaft, Berlin, Germany. The auditor has concluded that all legal requirements have been met and has granted an unqualified auditor's opinion.

Furthermore, the auditor has concluded that the Executive Board has implemented the measures incumbent upon it pursuant to Section 91 (2) of the German Stock Corporation Act (Aktiengesetz, AktG) regarding the establishment of a risk-monitoring system in a suitable form and that this system is suitable for the early detection of developments that endanger the continued existence of the company as a going concern. In regard to the report presented by the Executive Board on the company's relationships to affiliated enterprises in accordance with Section 312 AktG (affiliated company report), the auditor has confirmed that the statements made in the report are correct and that the payments made by the company for the legal transactions listed in the report were not inappropriately high.

The annual financial statements, including the affiliated company report and the auditor's audit report, were submitted to the Supervisory Board. A representative of the auditor took part in the Supervisory Board's balance-sheet meetings on 24 and 29

March 2022and reported on the key findings of the audit. The Supervisory Board acknowledged and approved the auditor's results.

Based on its subsequent examination, the Supervisory Board raises no objections against the audited annual financial statements and the affiliated company report, including the Executive Board's concluding statement. The Supervisory Board therefore approved the annual financial statements of Eckert & Ziegler Strahlen- und Medizintechnik AG and the consolidated financial statements of the Eckert & Ziegler Group. The annual financial statements of Eckert & Ziegler Strahlen- undMedizintechnik AG are thereby adopted. The Supervisory Board concurs with the

Executive Board's recommendation on the appropriation of net profit.

ACKNOWLEDGMENT

The Supervisory Board would like to thank the Executive Board and all employees for their outstanding performance in the financial year 2021.

Berlin, March 2022

For the Supervisory Board

Prof. Dr. Wolfgang Maennig Chairman of the Supervisory Board